News | Radiation Oncology | July 31, 2019

Laura Dawson, M.D., FASTRO, Chosen as ASTRO President-elect

Society members also elect three new officers to the ASTRO Board of Directors

Laura Dawson, M.D., FASTRO, Chosen as ASTRO President-elect

July 31, 2019 — The members of the American Society for Radiation Oncology (ASTRO) elected four new officers to ASTRO’s Board of Directors. Laura Dawson, M.D., FASTRO, will begin her term as president-elect in September during ASTRO’s 61st Annual Meeting, Sept. 15-18 in Chicago, alongside Neha Vapiwala, M.D., the new secretary/treasurer-elect; Constantine Mantz, M.D., the new health policy council vice-chair; and Brian Marples, Ph.D., the new science council vice-chair.

“I am honored to be elected as ASTRO’s President-elect. Radiation oncology is a highly effective intervention that most cancer patients benefit from at some point during the course of their disease. Unfortunately, not all patients have access to radiation therapy, and there is a need for improved public awareness about its benefits," said Dawson.

In her tenure as president-elect and eventual chair of ASTRO, Dawson also plans to address key challenges facing both radiation oncology and the larger house of medicine, including physician burnout, restrictive prior authorization practices and workforce diversity.

Dawson leads a multidisciplinary team of cancer specialists in upper gastrointestinal (GI) cancers at the Princess Margaret Cancer Centre in Toronto and is a professor of radiation oncology at the University of Toronto. She also directs the palliative radiation oncology program and has led numerous phase I, II and III trials, including trials that focused on the use of personalized stereotactic body radiation therapy (SBRT) for patients with liver cancer, who historically were not candidates for radiation therapy.

Dawson has an extensive record of service to ASTRO and the field. She previously served on the ASTRO board as chair of the education council. A leading expert in GI cancers, she recently chaired the steering committee of the Gastrointestinal Cancers Symposium co-sponsored by ASTRO. Dawson also has participated in the NRG's GI steering and translational research committees and the National Cancer Institute (NCI)/National Institute of Health (NIH) hepatobiliary task force for more than a decade.

Neha Vapiwala (secretary/treasurer-elect) is an associate professor and vice-chair of education in the department of radiation oncology and dean of admissions at the Perelman School of Medicine at the University of Pennsylvania. A nationally-recognized expert in genitourinary (GU) cancers, Vapiwala serves on the National Cancer Institute's Prostate Cancer Task Force and has led multiple large research projects covering a range of topics in radiation oncology. She also serves on the editorial board of JAMA Oncology and the National Comprehensive Cancer Network (NCCN) panel on early detection of prostate cancer.

Vapiwala has written extensively on issues affecting medical education and training from the undergraduate through professional levels. She is a member of ASTRO's workforce, education and international education committees, as well as the newly elected chair of the Accreditation Council for Graduate Medical Education's (ACGME) Radiation Oncology Residency Review Committee. Vapiwala also recently served as president of the Association of Directors of Radiation Oncology Programs (ADROP).

In her tenure on the ASTRO Board, Vapiwala plans to help the organization address increasing challenges in healthcare economics, the emergence of artificial intelligence and its role in radiation oncology, and renewed questions about the science of cancer and radiation therapy in an age of rapidly advancing technologies.

Constantine (Connie) Mantz (health policy council vice-chair) is chief policy officer and a radiation oncologist at 21st Century Oncology in Ft. Meyers, Fla., where he is involved in key administrative projects related to payer contracting, revenue cycle management, business intelligence and compliance. A former chair of ASTRO's Payer Relations Committee, Mantz has served on each of the organization's health policy committees. In his new board role, Mantz will work to address payment reform issues, including the implementation of an alternative payment model (APM) for radiation oncology and ASTRO's ongoing efforts to rein in restrictive prior authorization practices by health insurers.

Read the article “CMS Proposes New Alternative Payment Model for Radiation Oncology”

Brian Marples (science council vice-chair) is a research professor and director of radiobiology in the Department of Radiation Oncology at the University of Miami Miller School of Medicine. Marples is the senior biology editor for the ASTRO flagship journal, the International Journal of Radiation Oncology • Biology • Physics, and has led or served on several of ASTRO's science and education committees. As a board member, Marples will continue his focus on engaging ASTRO members, other leading medical societies and the public about innovations in radiation oncology, such as new technologies and treatments that combine radiation with immunotherapy.

Dawson will serve a one-year term as president-elect, followed by a single-year term as president, then one as chair of the ASTRO Board. Vapiwala will serve a one-year term as secretary/treasurer-elect followed by a three-year term as secretary/treasurer. Mantz and Marples will serve two-year terms as vice-chair, followed by two-year terms as chairs of their respective councils.

For more information: www.astro.org

Related Content

Newly released study results present a strong case for lung cancer screening in New Zealand — particularly for Māori whose mortality rates are between three and four times higher than other ethnic groups.

Image courtesy of Siemens Healthineers

News | Lung Imaging | September 30, 2020
September 30, 2020 — Newly released study results present a strong case for...
he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

News | Radiation Oncology | September 29, 2020
September 29, 2020 — On Sept.
Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s